The U.K.-based drugmaker told PennLive the decision to close the facility was made to “consolidate volumes and generate efficiencies by moving the site’s production to our Guayama, Puerto Rico facility.”
The facility, which was used to make GlaxoSmithKline’s product Emergen-C, a vitamin C supplement, will be closed by the end of 2021.
Read the full article here.
More articles on pharmacy:
21 states reject $18B opioid settlement offer from McKesson, Cardinal, AmerisourceBergen
BCBS responds to physician pushback on mail-order pharmacy plan
The 20 most expensive drugs in the US in 2020
